Peania, August 5th 2008 - An important co-marketing agreement for the nitroglycerine transdermal system for angina pectoris was signed between Lavipharm and Pfizer Hellas. According to the terms of the agreement, the product will be sold in the Greek market by Pfizer's sales force and will be marketed under Lavipharm's international trademark Trinipatch. Trinipatch is produced in Lavipharm's plant in Peania and it will be sold by Pfizer Hellas early September.

Read more: http://www.lavipharm.gr/english/contact/index.asp?section=news&art_id=378

Or return to the HBio news page